Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07178847
Recruiting Not applicable

cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

NCT07178847 · tracked via the Priya Life Science France tracker
Sponsor
Centre Jean Perrin
Phase
Not applicable
Started
2025-10-13
Last updated
2026-09-11

Condition(s) studied

Locally Advanced Head and Neck Carcinoma

Investigational drug(s) / intervention(s)

blood sampling →

blood sampling: The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy

Study summary

The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.

The main question it aims to answer is :

\- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological).

Participants will :

* be included in the main study (Neck-TAR)
* have a blood sample 1 and 3-month after the end of treatment

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Selection Criteria: * Patient included in NeckTAR study * Written informed consent signed for NeckTAR-IN study * Affiliation to the French social security system

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
CH Henri Mondor Aurillac Aurillac CANTAL Recruiting
Centre Jean PERRIN Clermont-Ferrand Puy-de-Dôme Recruiting
Hôpital de la Croix-Rousse Lyon France Recruiting
CHU de Saint-Étienne Saint-Etienne France Recruiting

More Centre Jean Perrin trials in France

AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Active, not recruiting
Microbiota and the Lung Cancer Active, not recruiting
Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment Active, not recruiting
Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients Active, not recruiting
Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer Recruiting

Other trials for the same condition

Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07178847 on ClinicalTrials.gov ↗ ← All trials in France